Bengaluru, June 06, 2025 – Emcutix Biopharmaceuticals Ltd., a wholly owned subsidiary of Emcure Pharmaceuticals Ltd., announces its entry into the anti-acne skincare category with the launch of Flawlizo Xpert Acne Care. The range aims to redefine acne care with a science-driven and targeted approach.
The range includes Flawlizo Acne Spot Corrector, a fast-acting biphasic solution proven to visibly reduce early breakouts within three to five days, and Flawlizo Acne Care Moisturizing Gel, a non-comedogenic formulation enriched with natural extracts to hydrate acne-prone skin without clogging pores. Both products are developed for safe, effective, and convenient everyday use, catering to the growing demand for science-backed skincare solutions.
The Flawlizo Xpert Acne Care range also comprises five prescription-only products (℞) formulated with tretinoin—a gold-standard active pharmaceutical ingredient (API) sourced from Italy. These products are manufactured at the facility of Encube Ethicals Private Limited, a USFDA-registered global supplier. Encube is also recognized for having the largest manufacturing capabilities for pharmaceutical topical formulations.
Speaking about the new range, Sathya Narayanan, CEO of Emcutix Biopharmaceuticals Ltd., said, “At Emcutix, we are committed to bridging everyday skincare needs with clinical efficacy. With the Flawlizo range, we aim at delivering science-led, consumer-friendly products that empower individuals to manage acne effortlessly. The introduction of this range is a testament to our vision of making high-quality dermatology products accessible across India.”
With this launch, Emcutix continues to expand its product portfolio, reinforcing its mission to provide cutting-edge skincare innovations that cater to prescription, aesthetic, and consumer segments. Recently, the company signed an exclusive licensing partnership with WiQo to import, promote, distribute, and sell a non-invasive skin treatment product, PRX-PLUS—the first of its kind made available in the Indian market.
